<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665674</url>
  </required_header>
  <id_info>
    <org_study_id>2014_TAZI</org_study_id>
    <nct_id>NCT04665674</nct_id>
  </id_info>
  <brief_title>Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study</brief_title>
  <official_title>Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH),&#xD;
      particularly survival, is largely unknown. This is the first prospective study in the field&#xD;
      evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based&#xD;
      study included a large cohort of PLCH patients followed for a sufficiently long period to&#xD;
      address risk factors of long-term outcomes of PLCH patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2004</start_date>
  <completion_date type="Anticipated">December 31, 2035</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2034</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>20 years</time_frame>
    <description>Overall survival defined as the time from inclusion to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CRF</measure>
    <time_frame>20 years</time_frame>
    <description>Cumulative incidence of chronic respiratory failure (CRF) from inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PH</measure>
    <time_frame>20 years</time_frame>
    <description>Cumulative incidence of pulmonary hypertension (PH) from inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignant diseases</measure>
    <time_frame>20 years</time_frame>
    <description>Cumulative incidence of Malignant diseases from inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra-pulmonary involvement in isolated PLCH</measure>
    <time_frame>20 years</time_frame>
    <description>Cumulative incidence of extra pulmonary localisations from inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual prevalence</measure>
    <time_frame>20 years</time_frame>
    <description>Number of people with the disease at any time during a year</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Histiocytosis</condition>
  <condition>Histiocytosis, Langerhans-Cell</condition>
  <condition>Histiocytosis Pulmonary</condition>
  <arm_group>
    <arm_group_label>Pulmonary Langerhans cell histiocytosis (PLCH)</arm_group_label>
    <description>All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older) referred to the French national reference centre for Histiocytoses</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)</description>
    <arm_group_label>Pulmonary Langerhans cell histiocytosis (PLCH)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with newly diagnosed PLCH at adulthood (i.e. 18 years of age or older)&#xD;
        referred to the French national reference centre for Histiocytoses&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved&#xD;
             tissue, or based on the combination of the following criteria: 1) an appropriate&#xD;
             clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed&#xD;
             tomography (HRCT) and 3) exclusion of alternative diagnoses&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdellatif TAZI, MD PhD</last_name>
    <phone>142499198</phone>
    <phone_ext>33</phone_ext>
    <email>abdellatif.tazi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>matthieu resche-rigon, MD PhD</last_name>
    <phone>142499742</phone>
    <phone_ext>33</phone_ext>
    <email>matthieu.resche-rigon@u-paris.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>French national reference centre for Histiocytoses</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdellatif TAZI, MD PhD</last_name>
      <phone>142499198</phone>
      <phone_ext>33</phone_ext>
      <email>abdellatif.tazi@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu RESCHE-RIGON, MD PhD</last_name>
      <phone>142499742</phone>
      <phone_ext>33</phone_ext>
      <email>matthieu.resche-rigon@u-paris.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

